SuperworthStarling Oncology shares outstanding STLN
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 103M
- On a year earlier
- +10.5%
- more shares
Starling Oncology had 103M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 10.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 101.5M | +34% |
| FY2024 | 75.7M | +2% |
| FY2023 | 74M | +2% |
| FY2022 | 72.8M | +4% |
| FY2021 | 69.9M | −5% |
| FY2020 | 73.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 103M | +11% | |
| Q1 FY26 | 101.8M | +32% | |
| Q4 FY25 | 101.5M | +34% | |
| Q3 FY25 | 97.5M | +29% | |
| Q2 FY25 | 93.2M | +25% | |
| Q1 FY25 | 77.1M | +4% | |
| Q4 FY24 | 75.7M | +2% | |
| Q3 FY24 | 75.5M | +3% | |
| Q2 FY24 | 74.7M | +1% | |
| Q1 FY24 | 74.2M | +1% | |
| Q4 FY23 | 74M | +2% | |
| Q3 FY23 | 73.5M | −8% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Starling Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.